CarbGeM Participates in a Panel Discussion at the Event Co-Hosted

by “Triple I for Global Health” and the Office of Healthcare Policy, Cabinet Secretariat Global Health and Impact Investment: Triple I’s Collaborative Path Forward

CarbGeM Inc. (hereinafter “CarbGeM”) is pleased to announce that Masakazu Nakajima, CEO, participated as a panelist in the event “Global Health × Impact Investment: Triple I’s Collaborative Path Forward,” co-hosted by Triple I for Global Health and the Office of Healthcare Policy, Cabinet Secretariat, held in Tokyo in November 2025.
________________________________________

Event Overview

The Triple I (Impact Investment Initiative for Global Health) is a G7 initiative launched on the occasion of the G7 Hiroshima Summit. Since its inception, it has aimed to expand impact investment in the global health sector by fostering collaboration among diverse stakeholders including domestic and international companies, international organizations, investors, and policymakers.

The initiative began in 2023 with 37 partner institutions and has now grown to include over 115 partners, including CarbGeM. Through hosting side events at the World Economic Forum (Davos), World Health Assembly, and United Nations General Assembly, as well as participating in impact investment events worldwide, Triple I has worked to enhance awareness and engagement in impact investment for global health.

This event shared the achievements of Triple I over the past two years and showcased best practices from partner organizations, with the goal of further promoting recognition and participation among stakeholders—particularly Japanese institutions—and strengthening contributions to global health.

Additionally, the networking sessions encouraged collaboration between domestic companies, organizations, international institutions, and investors to enhance Japan’s global presence in the field of global health.
Triple I for Global Health Official Website: (リンク »)
________________________________________

CarbGeM’s Presentation

CarbGeM introduced digital health and health-tech implementation cases within the global health domain, presenting models that leverage private-sector technology to address field-level challenges.
As a Triple I partner, the company shared case studies of public–private partnerships (PPP) in which its digital solutions have been socially implemented through collaboration with healthcare providers and government agencies.
The presentation highlighted how Japanese startups can contribute to the international health ecosystem.

CarbGeM’s initiatives contribute to improving efficiency, standardization, and workforce development in fields such as infectious disease testing and medical DX (digital transformation). The company also exchanged perspectives on the potential for expanding these initiatives across emerging markets in Asia.
________________________________________

Future Outlook

CarbGeM will continue to strengthen collaboration with Triple I and other international networks to:
• Establish models leveraging Japan-originated digital health technologies to solve global health challenges
• Promote public–private partnership projects centered on Asian countries
• Create sustainable health innovation in collaboration with impact investment
Through AI and digital technologies, CarbGeM is committed to advancing the visualization and efficiency in healthcare, contributing to improved global medical access and the development of public health worldwide.
________________________________________

About CarbGeM Inc.

CarbGeM Inc. drives innovation in the life sciences through advanced technologies, including obtaining regulatory approval for Software as a Medical Device (SaMD).
The company promotes diagnostic support, R&D efficiency, and the standardization and automation of quality control in the life science field. By delivering accurate and rapid results, CarbGeM addresses social issues such as shortages of skilled technicians and regional disparities in healthcare access.

Leveraging AI technologies and digital platforms, CarbGeM strengthens collaboration among researchers and healthcare professionals, aiming to contribute to the resolution of global challenges such as antimicrobial resistance (AMR).

CarbGeM has received numerous awards, including the Tokyo Social Innovation Tech Award 2024, and continues to promote open innovation in collaboration with leading research institutions and industry–academia–government partners in Japan and abroad.

Headquarters: 1-5-13 Jinnan, Shibuya-ku, Tokyo, Japan
Representative: Masakazu Nakajima, CEO
URL: (リンク »)